Drugs Affecting Blood and Blood Formation Practice Questions

Q: All of the following are antiplatelet agents except which of the following?

Tranexamic acid. ***Tranexamic acid*** - **Tranexamic acid** is an **antifibrinolytic agent** that inhibits plasminogen activation, thereby preventing clot breakdown. - It works to **promote clot stability** and is used to reduce bleeding, rather than inhibit platelet aggregation. *Aspirin* - **Aspirin** is an **antiplatelet agent** that irreversibly inhibits **cyclooxygenase-1 (COX-1)**, reducing thromboxane A2 production. - This effectively prevents platelet aggregation and is used for primary and secondary prevention of cardiovascular events. *Clopidogrel* - **Clopidogrel** is a **P2Y12 inhibitor**, an antiplatelet agent that selectively and irreversibly blocks the ADP receptor on platelets. - This inhibition prevents activation of the GP IIb/IIIa complex, thereby reducing **platelet aggregation**. *Ticagrelor* - **Ticagrelor** is a **P2Y12 inhibitor**, an antiplatelet agent that reversibly binds to the ADP receptor on platelets. - It provides a rapid and potent inhibition of **platelet aggregation**, similar to clopidogrel but with a faster onset and offset of action.

Q: What was the first oral direct thrombin inhibitor to be developed and approved for clinical use?

Ximelagatran. ***Ximelagatran*** - **Ximelagatran** was the **first oral direct thrombin inhibitor** to be developed and approved for clinical use. - Despite its initial approval, it was later withdrawn due to concerns about **drug-induced liver injury**. *Indraparinux* - **Indraparinux** is a **synthetic heparin analog** and an **indirect Factor Xa inhibitor**, not a direct thrombin inhibitor. - It was developed as a long-acting anticoagulant but did not achieve widespread clinical adoption. *Dabigatran* - **Dabigatran** is currently a widely used **oral direct thrombin inhibitor**, but it was approved **after ximelagatran**. - It is often cited as the first of the modern non-vitamin K antagonist oral anticoagulants (**NOACs**) to be widely marketed, but not the very first to be developed and approved for clinical use. *Fondaparinux* - **Fondaparinux** is a synthetic **selective Factor Xa inhibitor**, structurally similar to the antithrombin-binding region of heparin. - It works indirectly by enhancing antithrombin's activity against Factor Xa, and is not a direct thrombin inhibitor.

Q: What is the mechanism of action of ticagrelor?

P2Y12 receptor antagonist. ***P2Y12 receptor antagonist*** - **Ticagrelor** is an **oral antiplatelet drug** that reversibly binds to the **P2Y12 ADP receptor** on platelet surfaces. - By blocking this receptor, it prevents **ADP-mediated platelet activation** and subsequent aggregation, reducing the risk of thrombotic events. *Cox inhibition* - **COX inhibitors** like **aspirin** prevent the synthesis of **thromboxane A2**, a powerful platelet aggregator. - This mechanism is characteristic of **NSAIDs** and **aspirin**, not ticagrelor. *GPIIB/IIIA inhibition* - **GPIIb/IIIa inhibitors** (e.g., abciximab, eptifibatide, tirofiban) directly block the final common pathway for platelet aggregation by preventing **fibrinogen binding** to the GPIIb/IIIa receptor. - While also an antiplatelet mechanism, this is distinct from ticagrelor's action on the P2Y12 receptor. *Inhibition of thromboxane synthase* - Inhibition of **thromboxane synthase** would reduce the production of **thromboxane A2**, similar to the effect of COX inhibition. - This is not the primary mechanism of action for ticagrelor; drugs like **dazoxiben** or **picotamide** act through this pathway.

Q: A PTT is required for monitoring of which of the following anticoagulants?

Heparin. ***Heparin*** - The **activated partial thromboplastin time (aPTT or PTT)** is the standard laboratory test used to monitor the anticoagulant effect of **unfractionated heparin**. - Heparin primarily acts by enhancing the activity of **antithrombin III**, which inactivates factors like thrombin (Factor IIa) and Factor Xa, affecting the intrinsic and common pathways of coagulation, which the PTT measures. *Streptokinase* - Streptokinase is a **fibrinolytic agent** not an anticoagulant, meaning it dissolves clots rather than preventing their formation. - Its therapeutic effect is not monitored by PTT, but rather by assessing the lytic state, often through **fibrinogen levels** or euglobulin lysis time. *Warfarin* - **Warfarin** is monitored by the **prothrombin time (PT)** and subsequent international normalized ratio (INR). - Warfarin inhibits **vitamin K-dependent clotting factors** (II, VII, IX, X), which are primarily assessed by the PT. *Tranexamic acid* - Tranexamic acid is an **antifibrinolytic agent** that inhibits plasminogen activation, thus preventing the breakdown of fibrin clots. - It works to promote clot stability and is not an anticoagulant; therefore, it is not monitored by PTT.

Q: What is the primary mechanism of action of heparin?

It enhances the action of antithrombin III.. **It enhances the action of antithrombin III.** - Heparin binds to **antithrombin III (ATIII)**, causing a conformational change that increases its affinity for clotting factors, particularly **thrombin (factor IIa)** and **factor Xa** [1, 2]. - This augmentation of ATIII's inhibitory activity is crucial for its anticoagulant effect, preventing the formation and propagation of clots [1].*It directly inhibits thrombin without cofactors.* - Directly inhibiting thrombin without cofactors describes the mechanism of direct thrombin inhibitors like **dabigatran**, not heparin. - Heparin requires the presence of **antithrombin III** as a cofactor for its anticoagulant activity [1].*It increases platelet aggregation.* - Heparin is an **anticoagulant** that works by preventing clot formation, which includes inhibiting platelet aggregation in some contexts, but its primary mechanism is not to increase it. - Medications that increase platelet aggregation are typically **procoagulant** agents, which is the opposite effect of heparin.*It has a half-life of 12-24 hours.* - Heparin, specifically **unfractionated heparin**, has a relatively short half-life, typically around **1 to 2 hours**, necessitating continuous intravenous infusion or frequent subcutaneous injections. - A half-life of 12-24 hours is more characteristic of some **low molecular weight heparins** or vitamin K antagonists like **warfarin**.

Q: A useful thrombolytic agent that leads to plasmin activation is:

Streptokinase. ***Streptokinase*** - **Streptokinase** is a **thrombolytic agent** that forms a complex with **plasminogen**, leading to the activation of **plasmin**. - **Plasmin** is an enzyme that degrades **fibrin clots**, thus breaking down thrombi. *Vitamin K* - **Vitamin K** is essential for the synthesis of **blood clotting factors** (II, VII, IX, X) in the liver. - It has a **pro-coagulant effect** and promotes clot formation, rather than breaking them down. - It is used to reverse warfarin anticoagulation and treat bleeding disorders. *Heparin* - **Heparin** is an **anticoagulant** that works by activating **antithrombin III**, which in turn inhibits various coagulation factors. - It **prevents the formation of new clots** and the extension of existing ones but does not directly dissolve them. *Aspirin* - **Aspirin** is an **antiplatelet agent** that inhibits **cyclooxygenase-1 (COX-1)**, thereby reducing the production of **thromboxane A2**. - This prevents **platelet aggregation** and clot formation but does not dissolve existing clots.

Q: In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?

Prevention of venous thrombosis and pulmonary embolism. ***Prevention of venous thrombosis and pulmonary embolism*** - Anticoagulants are highly effective in inhibiting the formation and extension of **venous thrombi**, thereby directly preventing **deep vein thrombosis (DVT)** and **pulmonary embolism (PE)**. - The mechanism of action targets the **coagulation cascade**, directly reducing the risk of these venous thromboembolic events, which are a major indication for anticoagulant therapy. *Prevention of recurrences of myocardial infarction* - While anticoagulants may play a secondary role, **antiplatelet agents** (e.g., aspirin, clopidogrel) are the primary therapy for preventing recurrent myocardial infarction, as **arterial thrombi** are predominantly platelet-rich. - Anticoagulants are used in specific high-risk situations post-MI (e.g., **atrial fibrillation**, left ventricular thrombus) but are not generally considered the primary preventive strategy. *Cerebrovascular accident* - The benefit of anticoagulants for stroke prevention is primarily significant in cases of **cardioembolic stroke** (e.g., due to **atrial fibrillation**) where they prevent clot formation in the heart. - For non-cardioembolic **ischemic strokes** (e.g., thrombotic or lacunar), antiplatelet agents are generally preferred for secondary prevention. *Retinal artery thrombosis* - **Retinal artery thrombosis** is often caused by **arterial atherosclerosis** and **embolism** from the carotid arteries or heart, where antiplatelet agents are typically primary. - The role of anticoagulants here is limited to specific causes like **atrial fibrillation** or in patients already on anticoagulation for other indications.

Q: Warfarin's mechanism of action is

Inhibiting Vitamin K dependent carboxylation. ***Inhibiting Vitamin K dependent carboxylation*** - **Warfarin** acts as an antagonist to **vitamin K**, competitively inhibiting the enzyme **vitamin K epoxide reductase**. - This prevents the **gamma-carboxylation** of vitamin K-dependent clotting factors (II, VII, IX, X, and proteins C and S), rendering them biologically inactive. *Chelating calcium ions* - **Calcium ions** are essential cofactors in the coagulation cascade, but warfarin does not directly affect their concentration or chelate them. - Anticoagulants that chelate calcium, such as **citrate**, are typically used *in vitro* (e.g., in blood collection tubes), not systemically. *Inhibiting antithrombin III activity* - This mechanism describes the action of **heparin** and its derivatives, which enhance the natural anticoagulant activity of **antithrombin III**. - Warfarin's primary action is on vitamin K metabolism, not on antithrombin III potentiation. *Inhibiting thrombin activity* - Direct thrombin inhibitors (**DTIs**), such as dabigatran and argatroban, directly bind to and inhibit the activity of **thrombin (factor IIa)**. - Warfarin's action is upstream in the coagulation cascade, affecting the synthesis of multiple clotting factors, including prothrombin (the precursor to thrombin).

Q: Heparin activates which factor(s)?

Antithrombin III. ***Antithrombin III*** - **Heparin** exerts its anticoagulant effect primarily by binding to and activating **antithrombin III (ATIII)**. - Activated **ATIII** then inactivates several coagulation factors, most notably **thrombin (Factor IIa)** and **Factor Xa**, preventing clot formation. *Factor IIa* - **Factor IIa** (thrombin) is a **target** of the heparin-antithrombin III complex, not directly activated by heparin. - Heparin-ATIII complex **inhibits** Factor IIa, preventing its procoagulant effects. *Factor IXa* - While **Factor IXa** is also inhibited by the **heparin-antithrombin III complex**, it is not directly activated by heparin. - The inhibition of Factor IXa contributes to heparin's overall anticoagulant effect, particularly in the intrinsic pathway. *Factor Xa* - **Factor Xa** is a **primary target** of the **heparin-antithrombin III complex**, leading to its inactivation. - Heparin does not activate Factor Xa; rather, it facilitates its rapid **inhibition** by antithrombin III.

Q: All of the following drugs can prolong bleeding time except which of the following?

Multivitamins containing Vitamin K. ***Multivitamins containing Vitamin K*** - **Vitamin K** is essential for the synthesis of **coagulation factors** (II, VII, IX, X) in the liver. - Supplementation with Vitamin K can **shorten bleeding time** by promoting proper clot formation, thereby counteracting any tendency for prolonged bleeding. *Cephalosporins* - Certain **cephalosporins**, particularly those with a methylthiotetrazole side chain (e.g., Cefamandole, Cefoperazone), can **inhibit vitamin K-dependent clotting factor synthesis** and interfere with platelet function. - This interference can lead to a **prolonged bleeding time** and an increased risk of hemorrhage. *Methylxanthines* - **Methylxanthines** such as **theophylline** and caffeine, can **inhibit platelet aggregation** and reduce **adenosine diphosphate (ADP)-induced platelet responsiveness**. - This **antiplatelet effect** can result in a **prolonged bleeding time**. *Anti-depressants* - Many **antidepressants**, especially **Selective Serotonin Reuptake Inhibitors (SSRIs)**, can **interfere with serotonin uptake by platelets**. - Serotonin is crucial for **platelet aggregation**, and its diminished uptake can lead to **platelet dysfunction** and a **prolonged bleeding time**.

Question 1

All of the following are antiplatelet agents except which of the following?

Accepted Answer

Tranexamic acid

Answer

Clopidogrel

Answer

Ticagrelor

Answer

Aspirin

Question 2

What was the first oral direct thrombin inhibitor to be developed and approved for clinical use?

Accepted Answer

Ximelagatran

Answer

Indraparinux

Answer

Fondaparinux

Answer

Dabigatran

Question 3

What is the mechanism of action of ticagrelor?

Accepted Answer

P2Y12 receptor antagonist

Answer

Cox inhibition

Answer

Inhibition of thromboxane synthase

Answer

GPIIb/IIIa inhibition

Question 4

A PTT is required for monitoring of which of the following anticoagulants?

Accepted Answer

Heparin

Answer

Streptokinase

Answer

Warfarin

Answer

Tranexamic acid

Question 5

What is the primary mechanism of action of heparin?

Accepted Answer

It enhances the action of antithrombin III.

Answer

It increases platelet aggregation.

Answer

It directly inhibits thrombin without cofactors.

Answer

It has a half-life of 12-24 hours.

Question 6

A useful thrombolytic agent that leads to plasmin activation is:

Accepted Answer

Streptokinase

Answer

Vitamin K

Answer

Heparin

Answer

Aspirin

Question 7

In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?

Accepted Answer

Prevention of venous thrombosis and pulmonary embolism

Answer

Prevention of recurrences of myocardial infarction

Answer

Prevention of cerebrovascular accident (stroke)

Answer

Retinal artery thrombosis

Question 8

Warfarin's mechanism of action is

Accepted Answer

Inhibiting Vitamin K dependent carboxylation

Answer

Chelating calcium ions

Answer

Inhibiting antithrombin III activity

Answer

Inhibiting thrombin activity

Question 9

Heparin activates which factor(s)?

Accepted Answer

Antithrombin III

Answer

Factor IXa

Answer

Factor Xa

Answer

Factor IIa

Question 10

All of the following drugs can prolong bleeding time except which of the following?

Accepted Answer

Multivitamins containing Vitamin K

Answer

Methylxanthines

Answer

Anti-depressants

Answer

Cephalosporins

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?